Alternatives to Editas Medicine

A clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.

Develops advanced gene editing and cell therapy solutions for rare genetic diseases.

Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology.

Developing gene editing therapies to lower cholesterol.

Scalable, one-time curative in-vivo gene editing therapies.

Developing gene editing therapies for rare genetic diseases.

Arrakis Bio is developing novel therapeutics for cancer and other diseases using a proprietary gene editing platform.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

VI Therapeutics is developing novel therapies for rare genetic diseases.

Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.

A clinical-stage biotechnology company developing in vivo gene editing therapies.

Leveraging the adaptive immune system to diagnose and treat disease.

A global oncology company developing and commercializing innovative cancer treatments.

Clinical-stage genetic medicine company developing AAV-mediated treatments for cardiovascular and Alzheimer's diseases.

Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling.

Biotechnology company focused on developing treatments for rare metabolic diseases.

Biopharmaceutical company focused on developing and commercializing innovative treatments for rare neurological disorders.

Guardant Health is a precision oncology company that develops and commercializes liquid biopsy tests for cancer detection, recurrence monitoring, and treatment selection.

Biotechnology company developing gene therapies and regenerative medicine for heart disease.

AI-powered platform for personalized cell therapy development and manufacturing.